Compare Gilead Sciences, Inc. (GILD) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Micron Technology, Inc. — how do they compare? Gilead Sciences, Inc. trades at $151.28 (market cap $182.40B), while Micron Technology, Inc. trades at $1,027.86 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 6.4× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Micron Technology, Inc. for 48 Days on average.
| GILD | MU | |
|---|---|---|
Market Cap | $182.40B | $1.17T |
Volume | 4,469,821 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $155.80 | $1.21K |
52-Week Low | $116.74 | $181.60 |
Typical Hold Time | 111 Days | 48 Days |
Enterprise Value | $205.46B | $1.13T |
Dividend Yield | 2.23% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Micron Technology (MU) trades at $1,026.85, down 5.62% over 24 hours, despite strong fundamental performance. The stock shows bullish technical signals with support at $1,020 and resistance at $1,064. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $33.42 surpassing the $31.77 estimate. Revenue surged to $37.38 billion in 2025 with net income of $8.54 billion, while analyst consensus remains strongly bullish with 82.85% buy ratings and a $1,590 price target.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Key risks include cyclical memory pricing and potential growth deceleration. The valuation at P/E 13.94 appears reasonable given robust profitability margins and projected 2026 revenue of $133.2 billion. Institutional sentiment supports further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
